3 Firms Steer Gilead's $300M Purchase Of Cancer Biz Stake
Gilead said Tuesday it will pay $300 million for a stake in cancer immunotherapies company Tizona Therapeutics and could acquire the rest of Tizona later, a deal put together by Ropes...To view the full article, register now.
Already a subscriber? Click here to view full article